Tramadol use is associated with enhanced postoperative outcomes in breast cancer patients: a retrospective clinical study with in vitro confirmation.

Tramadol use is associated with enhanced postoperative outcomes in breast cancer patients: a retrospective clinical study with in vitro confirmation.

Publication date: Dec 01, 2019

There is growing interest in the effect of postoperative analgesics on oncological outcomes after cancer surgery. We investigated the impact of tramadol after breast cancer surgery on recurrence and mortality and explored the mechanism by which tramadol affects cultured breast cancer cells in vitro.

Electronic medical records of patients who underwent breast cancer surgery between November 2005 and December 2010 at Severance Hospital in Korea were reviewed. Cox regression analyses were used to identify factors related to postoperative recurrence and mortality. We performed the sensitivity test with propensity score matching to adjust for selection bias. In addition, we investigated the effects of tramadol on human breast adenocarcinoma (Michigan Cancer Foundation-7 [MCF-7]) cells via assessment of cell viability, clonogenic assay, and cell cycle analysis in vitro.

Of 2588 breast cancer patients, 36.4% had received tramadol. Those who received tramadol had a 0.71-fold decreased risk of recurrence and a 0.56-fold decrease in mortality. The MCF-7 cell viability assays showed that tramadol had an anti-proliferative effect by cell cycle arrest, suppressing colony formation, and regulation of oestrogen and progesterone receptors. Tramadol induced apoptosis of MCF-7 cells via extracellular signal-regulated kinases by decreasing of 5-hydroxytryptamine (HT) receptor and transient receptor potential vanilloid-1 expression.

After breast cancer surgery, patients who received tramadol had a decreased risk of postoperative recurrence and mortality. The anti-tumour effect of tramadol appears to involve inhibition of proliferation, induction of apoptosis, and effects on 5-HT receptor and TRPV-1.

Kim, M.H., Oh, J.E., Park, S., Kim, J.H., Lee, K.Y., Bai, S.J., Song, H., Hwang, H.J., Kim, D.W., and Yoo, Y.C. Tramadol use is associated with enhanced postoperative outcomes in breast cancer patients: a retrospective clinical study with in vitro confirmation. 04287. 2019 Br J Anaesth (123):6.

Concepts Keywords
Adenocarcinoma Tumour
Analgesics Tumor
Apoptosis Surgery
Breast Breast surgery
Colony Psychoactive drugs
Cox Regression RTT
Extracellular Neurochemistry
Korea Analgesics
Michigan Cyclohexanols
Mortality Serotonin-norepinephrine reuptake inhibitors
Oestrogen Tramadol
Oncological Breast cancer
Progesterone Opioid
Receptor MCF-7
Receptors Breast surgery
Selection Bias Apoptosis
Tramadol
Transient Receptor Potential
Tumour

Semantics

Type Source Name
drug DRUGBANK Tramadol
disease MESH breast cancer
pathway KEGG Breast cancer
disease MESH cancer
disease MESH recurrence
pathway KEGG Cell cycle
drug DRUGBANK Progesterone
pathway KEGG Apoptosis
drug DRUGBANK Serotonin
disease MESH Adenocarcinoma
disease MESH Neoplasm Recurrence Local
disease MESH Postoperative Complications

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *